Abstract
The microtubule-associated protein (MAP) tau has been implicated in the pathology of numerous neurodegenerative diseases. In the past decade, the hyperphosphorylated and aggregated states of tau protein have been important targets in the drug discovery field for the potential treatment of Alzheimer’s disease. Although several compounds have been reported to reduce the hyperphosphorylated state of tau or impact the stabilization of tau, their therapeutic activities are remain to be validated. Recently, reduction of total cellular tau protein has emerged as an alternate intervention point for drug development and a potential treatment of tauopathies. We have developed and optimized homogenous assays, using the AlphaLISA and HTRF assay technologies, for the quantification of total cellular tau protein levels in the SH-SY5Y neuroblastoma cell line. The signal-to-basal ratios were 375 and 5.3, and the Z’ factors were 0.67 and 0.60 for the AlphaLISA and HTRF tau assays, respectively. The clear advantages of these homogeneous tau assays over conventional total tau assays, such as ELISA and Western blot, are the elimination of plate wash steps and miniaturization of the assay into 1536-well plate format for the ultra–high-throughput screening of large compound libraries.
Keywords: Alzheimer’ s disease, FRET-based assay, high-throughput screening assay, prions, neurodegenerative diseases, tau protein.
Current Alzheimer Research
Title:A High-Throughput Screening Assay for Determining Cellular Levels of Total Tau Protein
Volume: 10 Issue: 7
Author(s): Seameen J. Dehdashti, Wei Zheng, Joel R. Gever, Robert Wilhelm, Dac-Trung Nguyen, Gurusingham Sittampalam, John C. McKew, Christopher P. Austin and Stanley B. Prusiner
Affiliation:
Keywords: Alzheimer’ s disease, FRET-based assay, high-throughput screening assay, prions, neurodegenerative diseases, tau protein.
Abstract: The microtubule-associated protein (MAP) tau has been implicated in the pathology of numerous neurodegenerative diseases. In the past decade, the hyperphosphorylated and aggregated states of tau protein have been important targets in the drug discovery field for the potential treatment of Alzheimer’s disease. Although several compounds have been reported to reduce the hyperphosphorylated state of tau or impact the stabilization of tau, their therapeutic activities are remain to be validated. Recently, reduction of total cellular tau protein has emerged as an alternate intervention point for drug development and a potential treatment of tauopathies. We have developed and optimized homogenous assays, using the AlphaLISA and HTRF assay technologies, for the quantification of total cellular tau protein levels in the SH-SY5Y neuroblastoma cell line. The signal-to-basal ratios were 375 and 5.3, and the Z’ factors were 0.67 and 0.60 for the AlphaLISA and HTRF tau assays, respectively. The clear advantages of these homogeneous tau assays over conventional total tau assays, such as ELISA and Western blot, are the elimination of plate wash steps and miniaturization of the assay into 1536-well plate format for the ultra–high-throughput screening of large compound libraries.
Export Options
About this article
Cite this article as:
Dehdashti J. Seameen, Zheng Wei, Gever R. Joel, Wilhelm Robert, Nguyen Dac-Trung, Sittampalam Gurusingham, McKew C. John, Austin P. Christopher and Prusiner B. Stanley, A High-Throughput Screening Assay for Determining Cellular Levels of Total Tau Protein, Current Alzheimer Research 2013; 10 (7) . https://dx.doi.org/10.2174/15672050113109990143
DOI https://dx.doi.org/10.2174/15672050113109990143 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Escape, or Vanish: Control the Fate of p53 through MDM2-Mediated Ubiquitination
Anti-Cancer Agents in Medicinal Chemistry New Perspective on the Dual Functions of Indirubins in Cancer Therapy and Neuroprotection
Anti-Cancer Agents in Medicinal Chemistry Cytotoxic and Allergenic Potential of Bioactive Proteins and Peptides
Current Pharmaceutical Design Tyrosine Kinases as Molecular Targets to Inhibit Cancer Progression and Metastasis
Current Pharmaceutical Design miRNAs in Melanoma: Tumor Suppressors and Oncogenes with Prognostic Potential
Current Medicinal Chemistry MAP Kinase Pathways in Neuronal Cell Death
CNS & Neurological Disorders - Drug Targets 5-HT3 Receptors
Current Drug Targets - CNS & Neurological Disorders Role of Acetylcholinesterase Inhibitors in the Metabolism of Amyloid Precursor Protein
Current Drug Targets - CNS & Neurological Disorders An Integrative Systems Analysis of High-grade Glioma Cell Lines: TLRs, Wnt, BRCA1, Netrins, STXBP1 and MDH1 Provide Putative Molecular Targets for Therapeutic Intervention
Current Pharmacogenomics and Personalized Medicine Multimodality Imaging of RNA Interference
Current Medicinal Chemistry The Emerging Role of NRAS Mutations in Colorectal Cancer Patients Selected for Anti-EGFR Therapies
Reviews on Recent Clinical Trials Cholesterol, Alzheimers Disease, Prion Disorders: A menage a trois?
Current Drug Targets Modulating Mitochondria-Mediated Apoptotic Cell Death through Targeting of Bcl-2 Family Proteins
Recent Patents on DNA & Gene Sequences Garlic and its Active Compounds: A Potential Candidate in The Prevention of Cancer by Modulating Various Cell Signalling Pathways
Anti-Cancer Agents in Medicinal Chemistry Mitochondrial Biogenesis: A Therapeutic Target for Neurodevelopmental Disorders and Neurodegenerative Diseases
Current Pharmaceutical Design The Role of Mitochondria in Brain Aging and the Effects of Melatonin
Current Neuropharmacology Identification of Prognostic Biomarkers in Papillary Thyroid Cancer and Developing Non-Invasive Diagnostic Models Through Integrated Bioinformatics Analysis
MicroRNA Antineoplastic Potential of Medicinal Plants
Recent Patents on Biotechnology Metal Based Frameworks for Drug Delivery Systems
Current Topics in Medicinal Chemistry Disodium Phosphate of Novel Pyrazole-Linked Norcantharidin Analogs:Design, Synthesis and their Anticancer Evaluation
Letters in Drug Design & Discovery